timothy sykes logo

Stock News

TransCode Therapeutics: Ready for Takeoff?

Timothy SykesAvatar
Written by Timothy Sykes
Reviewed by Bryce Tuohey Fact-checked by Matt Monaco

TransCode Therapeutics Inc.’s shares are significantly influenced by the announcement of its $7.8 million private placement to advance clinical trials for oncology treatments. On Friday, TransCode Therapeutics Inc.’s stocks have been trading up by 21.95 percent.

Key Insights from Recent Developments

  • TransCode Therapeutics has made significant strides forward by initiating dosing of the first patient in the third cohort of their Phase 1 clinical trial for TTX-MC138, targeting microRNA-10b associated with various metastatic cancers. The increased dose for this cohort follows successful safety evaluations, with no significant toxicities reported.

Candlestick Chart

Live Update At 09:18:26 EST: On Friday, January 24, 2025 TransCode Therapeutics Inc. stock [NASDAQ: RNAZ] is trending up by 21.95%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

  • The company has resolved prior compliance issues with Nasdaq listing rules, thereby securing its continued presence on the Nasdaq Capital Market. They achieved compliance for minimum bid price and shareholders’ equity rules and received shareholder ratification of a past equity transaction.

  • TransCode is under Nasdaq’s monitoring to ensure ongoing compliance. As of now, they are advancing their lead therapeutic candidate, TTX-MC138, with a strong emphasis on validating their RNA therapeutics drug design for treating cancer.

Financial Indicators and Market Implications

As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.” This concept is fundamental to those looking to succeed in the financial markets. Emotions can cloud judgment and lead to impulsive decisions, but adhering to a consistent strategy helps mitigate these risks and fosters long-term success.

TransCode Therapeutics’ recent financial data shows a dynamic picture. The company’s revenue figures are not specified, but notable financial strength indicators present a mixed scenario. The enterprise value stands at approximately $2.08M, while the total debt to equity ratio is relatively low at 0.09, suggesting some leverage but manageable financial obligations.

Notably, the PE ratio is at 0.01, reflecting a dramatically undervalued position if earnings were significant, which might not be the case given the negative cash flows. The firm has a favorable quick ratio of 0.8, indicating it can meet short-term liabilities with its available assets. However, the concerning return on assets and equity ratios show negative figures, evidencing challenges in profitability and value creation.

More Breaking News

The income statement further depicts daunting figures with a negative net income from continuing operations and substantial operating expenses. Although there is a low leverage ratio, cash flow continues to reflect operational difficulties, with negative changes indicating pressure on liquidity.

Annotated Analysis of Stock Price Changes

Recent developments within TransCode Therapeutics have had a noticeable impact on its stock price. The introduction of a new dosage level in clinical trials and resolving compliance issues might have instilled a degree of investor confidence, reflecting positively in stock prices. However, considering the historical performance, stock prices have been volatile, indicative of investor sentiment driven by speculative news and performance updates.

The provided chart price data illustrates significant price swings over the recorded period, exemplifying the uncertain nature inherent in biotech stocks, especially those in trial phases. The stock opened at $3.5 on Jan 23, 2025, peaked impressively at $12.43, and then settled at a close of $5.5. Such drastic shifts highlight market reactions to news and trial developments.

Conclusion: Future Prospects and Cautionary Notes

In conclusion, while the recent events surrounding TransCode Therapeutics portray potential progress, they underscore the speculative and volatile nature of biotech trading. The advancements in their clinical trials and realization of Nasdaq compliance restore some trader confidence and suggest stability, yet caution should be exercised due to inherent risks within the sector. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.”

Traders eye potential opportunities and can remain hopeful that further trial successes may catalyze long-term growth, albeit balanced with the awareness of financial hurdles. As further updates unfold, the market will calibrate the perceived stock value of TransCode Therapeutics. For those compelling to engage, a strategy inclusive of critical price monitoring and financial diversification is advisable to mitigate industry risks.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Our traders will never trade any stock until they see a setup they like. Their strategy is to capture short-term momentum while avoiding undue risk exposure to a stock’s long-term volatility. This method is especially useful when trading penny stocks or other high-risk equities, where rapid gains can be made by understanding stock patterns, manipulation, and media hype. Whether you are an active day trader looking for key indicators on a stock’s next move, or an investor doing due diligence before entering a position, Timothy Sykes News is designed to help you make informed trading decisions.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:


How much has this post helped you?


Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”